ConductScience.org, home

Paper27445481

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.

Castaman G and 1 other. Ther Clin Risk Manag, 2016. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A. Papers, record 27445481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27445481

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A.
PubMed
Journal
Ther Clin Risk Manag
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.59
iCite
Revised in PubMed
2020-09-30
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Castaman GGiancarlo
2Linari SSilvia

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References74

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116990605A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.Blood2007https://conductscience.org/library/papers/16990605PubMed
222428722Biological therapies for von Willebrand disease.Expert Opin Biol Ther2012https://conductscience.org/library/papers/22428722PubMed
310494765Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.Thromb Haemost1999https://conductscience.org/library/papers/10494765PubMed
412551832Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.Haematologica2003https://conductscience.org/library/papers/12551832PubMed
517593277International workshop on immune tolerance induction: consensus recommendations.Haemophilia2007https://conductscience.org/library/papers/17593277PubMed
617123402Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.Haemophilia2006https://conductscience.org/library/papers/17123402PubMed
711781224Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.Blood2002https://conductscience.org/library/papers/11781224PubMed
818081826
The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Haemophilia2008https://conductscience.org/library/papers/18081826PubMed
916985172VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.Blood2007https://conductscience.org/library/papers/16985172PubMed
1012781551Haemophilias A and B.Lancet2003https://conductscience.org/library/papers/12781551PubMed
1119335752Hepatitis A and B immunization for individuals with inherited bleeding disorders.Haemophilia2009https://conductscience.org/library/papers/19335752PubMed
1219411636Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.Blood2009https://conductscience.org/library/papers/19411636PubMed
1321649797Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.Haemophilia2011https://conductscience.org/library/papers/21649797PubMed
143492222Epidemiological investigation of the prevalence of von Willebrand's disease.Blood1987https://conductscience.org/library/papers/3492222PubMed
1515306670Treatment of von Willebrand's Disease.N Engl J Med2004https://conductscience.org/library/papers/15306670PubMed
1624270421von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.J Clin Invest2013https://conductscience.org/library/papers/24270421PubMed
1718175280Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.Semin Thromb Hemost2007https://conductscience.org/library/papers/18175280PubMed
1818230755Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.Blood2008https://conductscience.org/library/papers/18230755PubMed
1924354480Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.Haemophilia2014https://conductscience.org/library/papers/24354480PubMed
2017687129Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.N Engl J Med2007https://conductscience.org/library/papers/17687129PubMed

See all 74 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
39545083Hemostats in the clinic.Bioeng Transl Med2024https://conductscience.org/library/papers/39545083PubMed
37332615Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.J Blood Med2023https://conductscience.org/library/papers/37332615PubMed
32607039Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).J Blood Med2020https://conductscience.org/library/papers/32607039PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
F72155PubTator's text mininghttps://conductscience.org/library/genes/2155NCBI Gene
F82157PubTator's text mininghttps://conductscience.org/library/genes/2157NCBI Gene
FGB2244PubTator's text mininghttps://conductscience.org/library/genes/2244NCBI Gene
GP1BA2811PubTator's text mininghttps://conductscience.org/library/genes/2811NCBI Gene
VWF7450PubTator's text mininghttps://conductscience.org/library/genes/7450NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27445481

GET https://conductscience.org/api/papers/v1/27445481/references?page=2